FDA Approval Status for Children
Nayzilam (midazolam nasal spray) is FDA-approved for seizure clusters in patients 12 years and older who have epilepsy. It is not approved for children under 12 due to insufficient safety and efficacy data from clinical trials.[1][2]
Use in Younger Children
Pediatric studies for Nayzilam focused on ages 12-17, showing similar pharmacokinetics to adults but with risks like respiratory depression. No approval or robust data exists for kids under 12; off-label use occurs in some epilepsy centers but lacks standardized guidelines and increases risks without proven benefits.[2][3]
Common Side Effects in Approved Ages
In patients 12+, side effects include somnolence (42%), headache (10%), nasal discomfort (9%), and upper respiratory infection (8%). Serious risks: respiratory depression, especially if combined with opioids or CNS depressants; monitor breathing post-dose.[1][4]
Risks Specific to Children
Children face higher risks of respiratory arrest, hypotension, and sedation-related falls. Nasal spray may cause epistaxis or discomfort, worsening in smaller nasal passages. Contraindicated with acute narrow-angle glaucoma or severe respiratory issues. Overdose risk rises with repeated dosing.[2][5]
What Doctors Consider Before Prescuring
Physicians weigh seizure cluster severity against risks, often preferring rectal diazepam (Diastat) for under-12s, which is FDA-approved from 2 years old. Nayzilam offers faster onset (10 minutes) and easier administration but requires caregiver training. Always consult a pediatric neurologist; not for routine seizures.[3][6]
Alternatives for Pediatric Epilepsy Rescue